Irritable bowel syndrome: Pathophysiology and current therapeutic approaches

Michael Camilleri, Alexander C. Ford

Research output: Chapter in Book/Report/Conference proceedingChapter

7 Scopus citations

Abstract

Irritable bowel syndrome (IBS) is a prevalent condition affecting 10-20% of adults in most countries; IBS results in significant morbidity and health care costs. IBS is a disorder of the brain-gut axis, and recent insights into the pathophysiological mechanisms include altered bile acid metabolism, neurohormonal regulation, immune dysfunction, alterations in the epithelial barrier, and secretory properties of the gut. There remains a significant unmet need for effective treatments, particularly for the pain component of IBS, although the introduction of drugs directed at secretion, motility, and a nonabsorbable antibiotic provides an option for the bowel dysfunction in IBS.

Original languageEnglish (US)
Title of host publicationHandbook of Experimental Pharmacology
PublisherSpringer New York LLC
Volume239
DOIs
StatePublished - Jan 1 2017

Publication series

NameHandbook of Experimental Pharmacology
Volume239
ISSN (Print)0171-2004
ISSN (Electronic)1865-0325

    Fingerprint

Keywords

  • Irritable bowel syndrome
  • Pharmacotherapy

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Camilleri, M., & Ford, A. C. (2017). Irritable bowel syndrome: Pathophysiology and current therapeutic approaches. In Handbook of Experimental Pharmacology (Vol. 239). (Handbook of Experimental Pharmacology; Vol. 239). Springer New York LLC. https://doi.org/10.1007/164_2016_102